Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03384225
Other study ID # 2016-221
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 1, 2016
Est. completion date July 31, 2022

Study information

Verified date October 2021
Source Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Contact Jieling Jiang, M.D.
Phone 86-21-37798987
Email jiangjieling66@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Aim: To evaluated if cladribine based conditioning (CBA) could decrease relapse after haploidentical allogeneic HSCT in high risk and refractory AML patients as compared with fludarabine based conditioning regimen(FBA). Study design: open-labed, prospective, multicenter, randomized control study Number of subjects: 60 each group Treatment: CBA group: CBA as HSCT conditioning which including cladribine 5mg/m2 day -6 to day -2 , busulfan(iv) 3.2mg/kg day-6 to day -3 and cytarabine 2g/m2 day-6 to day -2. FBA group: FBA as HSCT conditioning which including fludarabine 30mg/m2 day -6 to day -2, busulfan(iv) 3.2mg/kg day-6 to day -3 and cytarabine 2g/m2 day-6 to day -2.


Description:

Relapse is still the main reason of death for patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT), especially for those with high risk and refractory disease. Cladribine and fludarabine are both purine analogs used in treatment of AML. Two studies by the Polish Adult Leukemia Group (PALG) demonstrated that the addition of cladribine to DA (DAC) was associated with an increased complete remission (CR) rate and prolonged overall survival (OS) in the general AML population, with the most prominent effect in patients with unfavorable cytogenetics. Therefore we presume cladribine may more effective in eliminating leukemic cells so that reduce relapse after HSCT. Haploidentical HSCT was the main option for those without HLA matched donors and the number of haploidentical transplants has covered over fifty percent of all allogeneic transplants in China. We designed this study to evaluated if cladribine based conditioning (CBA) could decrease relapse after haploidentical HSCT in high risk and refractory AML patients as compared with fludarabine based conditioning regimen(FBA). Eligible patients in this study should between 18 to 60 years old with confirmed AML and fulfilled at least one criteria defining high risk or refractory disease.Patients have no HLA matched sibling or unrelated donors but have haploidentical donor. Patients will be excluded if they present any contraindication for HSCT, including respiratory failure, heart failure, liver or kidney function failure et al. To evaluate if CBA could decrease relapse after haploidentical HSCT in high risk and refractory AML patients as compared with FBA, 120 eligible patients will be randomized to two groups, the CBA group and the FBA group. Patients in the CBA group receive conditioning including cladribine 5mg/m2 day -6 to day -2 , busulfan(iv) 3.2mg/kg day-6 to day -3 and cytarabine 2g/m2 day-6 to day -2. While patients in the FBA group receive conditioning including fludarabine 30mg/m2 day -6 to day -2 , busulfan(iv) 3.2mg/kg day-6 to day-3 and cytarabine 2g/m2 day-6 to day -2. Graft versus host disease(GVHD) prophylactic regimen include ATG 2.5mg/kg d-4 to d-1, cyclosporine A and short term MTX. Patients will be followed up for 2 years and the primary end point is the cumulative relapse rate at 2 years. The second end points of the study include the overall survival, disease free survival and non-relapse mortality at 2 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date July 31, 2022
Est. primary completion date July 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. Diagnosis of AML confirmed by bone marrow cell morphology, immunology, cytogenetics and molecular biology (MICM). Blast crisis of chronic myeloid leukemia (CML) and AML transferred from myelodysplastic syndrome(MDS) or other diseases are also included. 2. AML with high risk cytogenetic abnormals, such as FLT3- ITD, et al. 3. Patients fulfilled at least one of the following criteria defining refractory AML:(1) primary induction failure (PIF) after 2 or more cycles of chemotherapy; (2) first early relapse after a remission duration of fewer than 12 months and refractory to salvage combination chemotherapy; (3) second or subsequent relapse . 4. Have no HLA matched siblings or unrelated donors, but have haploidentical donor. The donor must match the health conditions of hematopoietic stem cell donation (criteria of China Marrow Donor Program) and be willing to donate. 5. Performance status score no more than 2 (ECOG criteria). 6. Adequate organ function as defined by the following criteria:ALT, AST and total serum bilirubin <2×ULN (upper limit of normal), Serum creatinine and BUN <1.25×ULN. 7. Adequate cardiac function without acute myocardial infarction, arrhythmia or atrioventricular block, heart failure, active rheumatic heart disease and cardiac dilatation. 8. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment. 9. Willingness and ability to comly with scheduled visits, treatment plans, laboratory tests, and other study procedures. Exclusion Criteria: 1. Presence of any condition inappropriate for HSCT. 2. Presence of any fatal disease, including respiratory failure, heart failure, liver or kidney function failure et al. 3. Have no suitable donor. 4. Pregnancy or breast feeding. 5. Current treatment on another clinical trail. 6. Any other condition the investigator judged the patient inappropriate for entry into this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cladribine

Fludarabine

Busulfan

Cytarabine


Locations

Country Name City State
China Shanghai general hospital, Shanghai Jiaotong university school of medicine Shanghai Shanghai

Sponsors (8)

Lead Sponsor Collaborator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Changhai Hospital, Chengdu PLA General Hospital, Fujian Medical University Union Hospital, Tang-Du Hospital, Tongji Hospital, Wuhan Union Hospital, China, Xiangya Hospital of Central South University

Country where clinical trial is conducted

China, 

References & Publications (2)

Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M, Haus O. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012 Jul 10;30(20):2441-8. doi: 10.1200/JCO.2011.37.1286. Epub 2012 Apr 16. — View Citation

Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K; Polish Adult Leukemia Group (PALG). Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004 May;18(5):989-97. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary cumulative relapse rate at 2 year The percentage of all patients who are relapsed within 2 years after allogeneic HSCT. 2 years
Secondary overall survival at 2 year The percentage of all patients who are still alive 2 years after allogeneic HSCT. 2 years
Secondary disease free survival at 2year The percentage of all patients who are leukemia free 2 years after allogeneic HSCT. 2 years
Secondary non-relapse mortality at 2year The percentage of patients who are dead within 2 years of all reasons except relapse. 2 years
Secondary non-relapse mortality at 100days The percentage of patients who are dead within 100days of all reasons except relapse. 100 days
See also
  Status Clinical Trial Phase
Recruiting NCT05066958 - Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT Phase 1/Phase 2
Recruiting NCT05237258 - Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia N/A
Recruiting NCT06394011 - Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients Phase 2
Completed NCT01696084 - Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Phase 3
Active, not recruiting NCT02861417 - Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Phase 2
Recruiting NCT03384212 - CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML Phase 3